These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 11758671)

  • 21. Efferocytosis is impaired in Gaucher macrophages.
    Aflaki E; Borger DK; Grey RJ; Kirby M; Anderson S; Lopez G; Sidransky E
    Haematologica; 2017 Apr; 102(4):656-665. PubMed ID: 28011901
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease.
    Pandey MK; Burrow TA; Rani R; Martin LJ; Witte D; Setchell KD; Mckay MA; Magnusen AF; Zhang W; Liou B; Köhl J; Grabowski GA
    Nature; 2017 Mar; 543(7643):108-112. PubMed ID: 28225753
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exploring genetic modifiers of Gaucher disease: The next horizon.
    Davidson BA; Hassan S; Garcia EJ; Tayebi N; Sidransky E
    Hum Mutat; 2018 Dec; 39(12):1739-1751. PubMed ID: 30098107
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretome.
    Campeau PM; Rafei M; Boivin MN; Sun Y; Grabowski GA; Galipeau J
    Blood; 2009 Oct; 114(15):3181-90. PubMed ID: 19587377
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Twin pairs showing discordance of phenotype in adult Gaucher's disease.
    Lachmann RH; Grant IR; Halsall D; Cox TM
    QJM; 2004 Apr; 97(4):199-204. PubMed ID: 15028849
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A chimeric mouse model of Gaucher disease.
    Beutler E; West C; Torbett BE; Deguchi H
    Mol Med; 2002 May; 8(5):247-50. PubMed ID: 12359955
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage.
    Mizukami H; Mi Y; Wada R; Kono M; Yamashita T; Liu Y; Werth N; Sandhoff R; Sandhoff K; Proia RL
    J Clin Invest; 2002 May; 109(9):1215-21. PubMed ID: 11994410
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gaucher disease: new molecular approaches to diagnosis and treatment.
    Beutler E
    Science; 1992 May; 256(5058):794-9. PubMed ID: 1589760
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gaucher disease.
    Mignot C; Gelot A; De Villemeur TB
    Handb Clin Neurol; 2013; 113():1709-15. PubMed ID: 23622393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gaucher disease: the metabolic defect, pathophysiology, phenotypes and natural history.
    Baris HN; Cohen IJ; Mistry PK
    Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1(0 1):72-81. PubMed ID: 25345088
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glucocerebrosidase (Gaucher disease).
    Beutler E; Gelbart T
    Hum Mutat; 1996; 8(3):207-13. PubMed ID: 8889578
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of neurogenetics in Gaucher disease.
    Brady RO; Barton NW; Grabowski GA
    Arch Neurol; 1993 Nov; 50(11):1212-24. PubMed ID: 8215980
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Myoclonic epilepsy in Gaucher disease: genotype-phenotype insights from a rare patient subgroup.
    Park JK; Orvisky E; Tayebi N; Kaneski C; Lamarca ME; Stubblefield BK; Martin BM; Schiffmann R; Sidransky E
    Pediatr Res; 2003 Mar; 53(3):387-95. PubMed ID: 12595585
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gaucher disease in the neonate: a distinct Gaucher phenotype is analogous to a mouse model created by targeted disruption of the glucocerebrosidase gene.
    Sidransky E; Sherer DM; Ginns EI
    Pediatr Res; 1992 Oct; 32(4):494-8. PubMed ID: 1437405
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Experimental polymer storage disease in rabbits. An approach to the histogenesis of sphingolipidoses.
    Miyasaki K
    Virchows Arch A Pathol Anat Histol; 1975; 365(4):351-65. PubMed ID: 803739
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Viable mouse models of acid beta-glucosidase deficiency: the defect in Gaucher disease.
    Xu YH; Quinn B; Witte D; Grabowski GA
    Am J Pathol; 2003 Nov; 163(5):2093-101. PubMed ID: 14578207
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and biochemical pathophysiology of ataxia in the sphingolipidoses.
    Philippart M
    Adv Neurol; 1978; 21():131-49. PubMed ID: 104554
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alterations in the properties of the cell membrane due to glycosphingolipid accumulation in a model of Gaucher disease.
    Batta G; Soltész L; Kovács T; Bozó T; Mészár Z; Kellermayer M; Szöllősi J; Nagy P
    Sci Rep; 2018 Jan; 8(1):157. PubMed ID: 29317695
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Recent advances in sphingolipidosis research].
    Tamai Y; Kojima H
    Tanpakushitsu Kakusan Koso; 1990 May; 35(7 Suppl):1291-303. PubMed ID: 1972585
    [No Abstract]   [Full Text] [Related]  

  • 40. Gaucher disease in Romanian patients: incidence of the most common mutations and phenotypic manifestations.
    Drugan C; Procopciuc L; Jebeleanu G; Grigorescu-Sido P; Dussau J; Poenaru L; Caillaud C
    Eur J Hum Genet; 2002 Sep; 10(9):511-5. PubMed ID: 12173027
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.